CSS LLC’s Heron Therapeutics HRTX Stock Holding History

CSS LLC’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-46,200	Closed	-$195K	–	1016
2022 Q3	$195K	Hold	46,200	–	–	0.01%	754
2022 Q2	$129K	Buy	46,200 +38,400	+492%	+$154K	0.01%	862
2022 Q1	$45K	Buy	+7,800	New	+$57.1K	﹤0.01%	1019
2021 Q4	–	Sell	-20,000	Closed	-$214K	–	1275
2021 Q3	$214K	Buy	+20,000	New	+$243K	0.01%	861
2021 Q2	–	Sell	-59,000	Closed	-$956K	–	1121
2021 Q1	$956K	Buy	+59,000	New	+$1.05M	0.04%	409
2020 Q3	–	Sell	-200	Closed	-$3K	–	828
2020 Q2	$3K	Buy	+200	New	+$3.29K	﹤0.01%	642

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CSS LLC's HRTX Position: Q4 2022 in Review

CSS LLC sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 9,000 shares — an estimated $38K sold.

CSS LLC first reported a position in HRTX in Q2 2020 and held it in 8 quarters. The position peaked at $622K in Q1 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

CSS LLC reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
CSS LLC sold 9,000 Heron Therapeutics shares in Q4 2022, an estimated $38K.
CSS LLC first reported a position in Heron Therapeutics in Q2 2020 and held it in 8 quarters.
CSS LLC's Heron Therapeutics position peaked at $622K in Q1 2021.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.